Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss

Cisplatin is a platinum-based drug, which remains among the most efficacious anticancer treatment options. Unfortunately, use of cisplatin is hindered by dose-limiting toxicities, including irreversible hearing loss, which can grossly affect patient quality of life. Cisplatin-induced ototoxicity is the result of cochlear hair cell damage through a mechanism that is poorly understood. However, cisplatin cytotoxicity is reliant on intracellular accumulation, a process that is largely dependent on the presence of particular membrane transporters. This review will provide an update on our current understanding of the various transporters known to be involved in the disposition and cytotoxicity of platinum drugs or their metabolites, as well as their role in mediating cisplatin-induced hearing loss. We also provide a summary of the successes and opportunities in therapeutically targeting membrane transporters to alleviate platinum-induced hearing loss. Moreover, we describe how this approach could be used to reduce the severity or onset of other adverse events associated with exposure to various forms of platinum drugs, without diminishing antitumor efficacy. SIGNIFICANCE STATEMENT Cisplatin-induced hearing loss is a dose-limiting and irreversible adverse event with no current preventative or curative treatment measures. Pharmacological targeting of membrane transporters that regulate platinum uptake into cochlear hair cells, if conducted appropriately, may alleviate this devastating side effect and could be applied to alleviate other platinuminduced toxicities.

Automated summary

Cisplatin is an effective anticancer drug, but its use is limited by dose-limiting toxicities, including irreversible hearing loss. The mechanism behind cisplatin-induced ototoxicity is not fully understood, but it relies on the presence of specific membrane transporters for cellular accumulation. Targeting these transporters therapeutically has shown success in alleviating cisplatin-induced hearing loss and presents opportunities for mitigating other platinum-induced toxicities.